This discrepancy may be explained by the fact that in vivo the arrival of MDSCs to the tumor microenvironment is somewhat delayed and therefore the number of CD8 T cells in the control case is significantly less than in the J558-IL-35 case, while (for simplicity) our model does not include such a time delay. The gene discussed is CD8A; the disease is neoplasm.